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Cystic fibrosis (CF) is the most common autosomal recessive disorder caused due to mutation/s in
the CFTR gene. The most common mutation in CFTR worldwide is ΔF508 and cystic fibrosis
genetic analysis consortium revealed that this mutation is responsible for approximately 66% of all
CF chromosomes in the world. Studies looking at the DNA polymorphic haplotypes created by CF
linked markers suggest that ΔF508 has a single origin as this mutation has been found associated
exclusively with one marker haplotype. Despite a high prevalence of this mutation in CF patients
in northern parts of Europe, findings suggest that this mutation was not spread by Europeans but
by a group that is speculated to have originated in the Middle East or a more eastern region in Asia
(most likely subcontinent). Over here we have given a brief introduction to cystic fibrosis and
classification of CFTR mutations and have further elaborated on the crucial issue about the spread
of the ΔF508 mutation. We have reviewed findings that give clues about the origin of this
mutation from the Baluch ethnicity residing in Pakistan.
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Cystic fibrosis (CF) is the most common life-limiting
autosomal recessive disorder; it affects nearly 1/2500
live births in Caucasians.1 CF is a multi-system disease
and can involve secretory cells, sinuses, lungs,
pancreas, liver and the reproductive tract.1 The disease
has a “classical” appearance in 90% of cases and
patients present with a triad of chronic obstructive
pulmonary disease, exocrine pancreatic insufficiency
and elevation of sodium and chloride concentrations in
the sweat.1–3 After extensive research in the field, in
western countries, 60% of all CF patients have a
diagnosis of the disease before their first birthday and
90% of all CF patients are diagnosed by 10 years of
age. This has greatly affected the life expectancy of CF
patients as compared to the past.1
The first evidence of CF being a monogenic
disorder came from the reviews of CF pedigrees in
Italian church records in 1985.2 Later on identification
and cloning of the CFTR gene on chromosome 7
served as the basis for understanding the genetic
aetiology of the disease.4–5 The gene causing CF spans
190 Kb of DNA and encodes a 1480 amino acid
polypeptide named cystic fibrosis transmembrane
regulator (CFTR).6 To date 1529 mutations have been
identified in the gene.7 These mutations have a variety
of effects at the cellular level. However they can be
grouped into 6 categories8, in which they:
i. block the synthesis of CFTR,
ii. lead to defective processing
iii. cause abnormal regulation of CFTR Cl channel
iv. disrupt the normal conductive pathway of the
channel
v. lead to complete or partial production of CFTR
protein
vi. lead to defective regulation of other channels.

The most common mutation in CFTR
worldwide is ΔF508.1 It is a class II mutation caused
by deletion of three bases encoding a phenylalanine
residue at position 508 within the nucleotide binding
domain (NBD).9 Heterologous expression system
analyses have shown that this mutation results in misfolding of the CFTR and hence mislocalization and
defective processing of the mature protein.9 It was
postulated that the mutation is severe enough to result
in absence of any mature protein in the affected
cells.10 Recent immuno-cytochemical studies of
intestinal, respiratory and hepatobiliary epithelia,
however, show that in patients homozygous for Δ
F508, a proportion of CFTR protein was shown to be
targeted to the apical membranes.11 The fact was lent
support by in vitro studies done on ΔF508
homozygous CF patients suggesting that at least
some CFTR molecules reach the plasma membrane
in these patients.12 Genotype-phenotype correlations
clearly indicate that this mutation is severe as far as
pancreatic status is concerned but conclusions on its
effect on lung disease vary between studies.8.
Cystic fibrosis genetic analysis consortium
revealed that ΔF508 is responsible for approximately
66% of all CF chromosomes in the world.13 However
its frequency varies from region to region.13 The
highest frequency has been found in patients from
Northern Europe, where it accounts for 75%-88% of
all CF alleles.14 Indeed, the frequency reaches to a
maximum of 100% in the isolated Faroe Islands of
Denmark.15 Importantly, evaluation of studies that
have been done on European populations reveal a
clear-cut north-west to south-east gradient of ΔF508
prevalence in CF patients showing a maximum
prevalence of 88% in Denmark (excluding Faroe
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islands) to a minimum of 24.5% in the Turkish
population.13–15
Although studies investigating the origin of
ΔF508 have failed to identify any founder population
but have established strong evidence in ruling out
various potential regions (for eg. Faroe islands)
where the mutation could have possibly
originated.13,16–19 These DNA based studies normally
utilize single nucleotide polymorphisms (SNP’s) and
several short tandem repeat polymorphisms which
are also known as ‘microsatellites’ within a gene of
interest to find and trace the origin of a mutation. By
utilizing such a methodology, evolutionary origin of
some CF causing mutations have been identified; for
instance CFTR mutation G542X had a single origin
in the ancient Phoenicians.20 Similarly CFTR
mutation G551D has been associated with Celtic
tribes.21
SNP’s or microsatellite markers by virtue of
linkage disequilibrium can be used to create haplotypic
maps. A haplotype containing a CFTR mutation or a
SNP linked with a CFTR mutation displays a
geographical gradient starting from a higher frequency
in the founder population residing in a specific region
to a lower frequency in a region where migration from
the prior region has occurred lately. Based on this
principle ancestry of a CFTR mutation G551D was
revealed, as one particular haplotype containing this
mutation remained unaltered from more than 170
generations and displayed variable frequencies in
different regions.20,22
Studies looking at the DNA polymorphic
haplotypes created by CF linked markers suggest that Δ
F508 has a single origin.16 This mutation has been found
associated exclusively with one marker haplotype.
Morral et al. have suggested that the original time of
this mutation ranges from 3000 years to 53000 years
ago.16 Despite a high prevalence in northern parts of
Europe, findings suggest that the mutation is more
ancient and did not originate in Europe.16–19 Moreover,
analyses of wild type chromosome containing CFTR
gene of various European populations suggest that the
general genetic background of these populations is
different than the diseased CFTR chromosome and thus
the origin of most frequent CF mutations should be nonEuropean.17–18
Based on these findings, Mateu et al.
investigated the origins of five common CFTR
mutations including ΔF508 in 949 unrelated
autochthonous healthy individuals of various
geographical origins and concluded that the haplotype
containing ΔF508 was present in very low frequencies
in the European populations.19 However, the highest
frequency was detected in one Middle Eastern
population.19 Although Mateu et al. did not report the
data on the different Middle Eastern ethnicities, a
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comprehensive pattern of CF causing mutations in two
Middle Eastern regions has been reported by Frossard
et al.23,24 The data from Middle East show high
frequencies of Δ F508 in particular ethnicities. Despite
the fact that data reported by Frossard et al. does not
show the haplotype frequencies, it is now widely
believed that Δ F508 is more ancient and that it was
not spread by Europeans but by a group that preceded
them.16–19,21,23 This group is speculated to have
originated in the “Middle East” or a more eastern
region in Asia (most likely subcontinent).23,25 Thus it is
important to study this mutation along with specific
haplotypes in the CF patients of Middle East, Pakistani
and Indian origin to discover more about its origins.
Studies on CF in indigenous subcontinental
population are severely lacking. Two studies have been
done in this regard looking at the prevalence of ΔF508
prevalence in CF patients. Both studies were done on
patients who were admitted to tertiary care hospitals. In
both the studies the patients were diagnosed of CF by
pilocarpine iontophoresis test initially. Study done by
Bhutta ZA et al on Pakistani population was limited to
very small sample size.26 They evaluated 15 patients
belonging to different ethnicities in Pakistan and found a
60% prevalence of this mutation in the Pakistani CF
population. The other study done by Kabra SK et al
looked at a patient population coming from different
regions of India and Pakistan. ΔF508 was identified in
19% chromosomes out of 290 tested.27 It is surprising to
note that ΔF508 was highest (56%) in patients of
Pakistani origin as compared to a 12% prevalence of
this mutation in Indian CF patients.27 Findings of both
studies could be challenged on the fact that ΔF508 is a
severe mutation as far as pancreatic status is concerned
and patients carrying this mutation are hence more
likely to be hospitalized compared to those with milder
mutations, which would confer a spuriously high
prevalence of ΔF508 in a hospital-based sample
population. A 42% difference in prevalence between
Pakistani and Indian CF populations, however, cannot
be ignored.
It must be kept in mind that the ‘Pakistani
population’ does not have a homogenous distribution
and is composed of people belonging to different
ethnicities. It is highly essential to look at the individual
ethnic data while studying the genetic mutation
spectrum of a disorder like CF. Studies looking at the
ΔF508 prevalence in CF patients of Pakistani origin
living overseas have been variable and have looked at
heterogeneous Pakistani populations rather than
individual ethnicities. The most striking evidence of a
high prevalence of ΔF508 in a Pakistani ethnic group
comes from the findings of Frossard et al., who studied
CF genetic mutations in the United Arab Emirates.23
They investigated 17 unrelated families and found a
86% prevalence (14/16 alleles) of ΔF508 in Baluchis
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residing in UAE. Out of this Baluch population, all
Pakistani Baluch CF patients carried ΔF508 mutation
(100% prevalence). These findings were subsequently
confirmed in the Omani population, in which 100% of
CF patients of Baluch origin were also ΔF508
homozygotes.24 Keeping in view the findings discussed
earlier about a non-European origin of ΔF508 and a
high prevalence of ΔF508 found in Pakistani Baluchis,
it has been proposed that this mutation might have
originally arisen in Baluchis. This hypothesis is
analogous to the findings of Quaife et al.28 who studied
the spectrum of beta-thalessemia in the UAE population
and concluded that some specific mutations were
introduced into UAE population by Baluchi immigrants.
The Baluch ethnicity currently resides in Iran,
Pakistan (Baluchistan) and Afghanistan, and its people
are known to have immigrated through successive
waves to the Punjab, India and Gulf countries (Oman
and the UAE). However, the actual geographical
location of Baluchis refers only to the western
province of Pakistan, Baluchistan. To prove a founding
effect of ΔF508 mutation in the Pakistani Baluch
population, it is highly essential to study Baluchis of
Pakistani province Baluchistan using appropriate
haplotype analyses. This will answer the crucial
question in the field of CF to know whether indeed
‘Baluchistan’ was the cradle of the ΔF508 mutation.
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Figure-1: Starred line represents approximate
boundaries of the Baluch ethnicity. The arrow
indicates the migrations that occurred historically
from Baluchistan to Oman and the UAE.
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